Provectus Biopharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2024 | — | $-6.0M | $307.4K |
| FY2025 | — | $-6.3M | $251.3K |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2024 | — | $-6.0M | $307.4K |
| FY2025 | — | $-6.3M | $251.3K |